Novel combinations of PI3K-mTOR inhibitors with dacomitinib or chemotherapy in PTEN-deficient patient-derived tumor xenografts

PTEN inactivation occurs commonly in human cancers and putatively activates the PI3K/AKT/ mTOR pathway. Activation of this pathway has been involved in resistance to chemotherapy or anti-EGFR/HER2 therapies. We evaluated the combination of PI3K-mTOR inhibitors with chemotherapy or the pan-HER inhibi...

Descripción completa

Detalles Bibliográficos
Autores principales: Brana, Irene, Pham, Nhu-An, Kim, Lucia, Sakashita, Shingo, Li, Ming, Ng, Christine, Wang, Yuhui, Loparco, Peter, Sierra, Rafael, Wang, Lisa, Clarke, Blaise A., Neel, Benjamin G., Siu, Lillian L., Tsao, Ming-Sound
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Priority Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5689564/
https://www.ncbi.nlm.nih.gov/pubmed/29156674
http://dx.doi.org/10.18632/oncotarget.19109

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5689564/
https://www.ncbi.nlm.nih.gov/pubmed/29156674
http://dx.doi.org/10.18632/oncotarget.19109

Ejemplares similares